Daniel Nixon

Dr. Daniel Nixon

Morehouse School of Medicine, Atlanta, GA 30310, USA
orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2018 in Brain Sciences
Verified
Journal Article
Open access
PDF file
Daniel NixonDaniel Nixon
Daniel Nixon
Down syndrome (trisomy 21), a complex mix of physical, mental, and biochemical issues, includes an increased risk of Alzheimer’s disease and childhood leukemia, a decreased risk of other tumors, and a high frequency of overweight/obesity. Certain features related to the third copy of chromosome 21 (which carries the APP gene and several anti-angiogenesis genes) create an environment favorable for Alzheimer’s disease and unfavorable for cancer. This environment may be enhanced by two bioactive compounds from fat cells, leptin, and adiponectin. This paper outlines these fat-related disease mechanisms and suggests new avenues of research to reduce disease risk in Down syndrome.

1 January 1990 in Nutrition and Cancer
Verified
Journal Article
Closed access
ASArline D. Salbe
Arline D. Salbe
DADemetrius Albanes
Demetrius Albanes
MWMyron Winick
Myron Winick
PTPhilip R. Taylor
Philip R. Taylor
Daniel NixonDaniel Nixon
Daniel Nixon
OLOrville A. Levander
Orville A. Levander
Both selenium and calorie restriction are anticarcinogenic in many tumor models, but the mechanisms of action are unknown. This study compared the effects of elevated selenium (Se) intake and calorie restriction on coionic cellular growth. Female weanling rats were divided into four groups: control, 40% calorie restricted, and 4 or 6 mg Se/l H2O as selenate. Control rats and rats given Se consumed the control diet ad libitum. Rats in the 40% calorie‐restricted group were pair fed 40% less than the total intake of control rats with a diet designed to provide equal nutrients except calories from carbohydrate. After three weeks, rats were injected with [3H]thymidine (1 μCi/g body wt) and killed one hour later. Se at 4 and 6 mg/l H2O and 40% calorie restriction significantly decreased food intake, weight gain, colon weight, and total colon DNA compared with controls. Total number of cells per crypt was not affected by any treatment, whereas total DNA synthesis was significantly decreased, suggesting that the total number of coionic crypts are reduced by calorie restriction and Se treatment. The rate of cell division was decreased only in rats given 6 mg Se/l H2O. These results indicate that elevated Se intake and caloric restriction decrease coionic mucosal growth by decreasing growth in general, but only very high intakes of Se affect coionic cell turnover.

1 November 1994 in Cancer
Verified
Journal Article
Open access
Daniel NixonDaniel Nixon
Daniel Nixon
The results of early cancer prevention trials now are being reported, and new trials have begun or are being designed. Initial trials used agents such as vitamins and minerals, generally regarded as safe. The trials in progress are using similar agents or macronutrient manipulation, but some have incorporated drugs with low but definite toxic potential, such as tamoxifen. Appropriate prevention trial design requires careful consideration of agent toxicity and the use of such agents in healthy individuals. Full disclosure of risks and benefits to potential subjects is necessary. Other considerations are study duration (usually very long) and subject number (usually very large), both of which increase the cost of a trial. Successful prevention trials must overcome these barriers through innovative design. Possible innovations include the use of intermediate marker end-points, the enrollment of subjects at high risk for a specific cancer, and the use of volunteers to help conduct trials.

20 May 2018 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
EMEleanor Meisner
Eleanor Meisner
RRRebecca Rollins
Rebecca Rollins
JEJoe Ensor
Joe Ensor
AMAmber Moran
Amber Moran
AWAmanda Woodward
Amanda Woodward
RARicardo H. Alvarez
Ricardo H. Alvarez
1074 Background: A recent Phase III study in MBC with gBRCAm, olaparib monotherapy provided a statistical significant and clinically meaningful PFS benefit compared to standard physician of choice treatment. (Robson M, NEJM 2017) Recently, olaparib was FDA approved for MBC with gBRCAm. Methods: IRB-approved analysis of pts underwent to genomic or genetic analysis. Retrospective review charts for pts with MBC who had received ≥2 chemotherapy lines for MBC were tested with genomic or genetic studies. The objective of this analysis was to determine the PFS2/PFS1 ratio. [von Hoff DD, 2014]. lBRCAm were detected in 12 out 19 pts [8 Foundation One, 3 Foundation Act and 1 Guardant 360] where somatic versus germline nature was not determined and gBRCAm 7 out 19 pts. Results: From 03/2014 to 08/2017, 319 pts with advanced cancer were treated with targeted therapy based on molecular abnormality. Overall 19 out 319 (6%) consisted on olaparib for MBC with gBRCAm or lBRCAm. Median age 45.1 years (range, 31-67), 18 out 19 pts were female, 14/19 were Caucasians, median number of previous lines of treatment for MBC was 4 (range, 2-8). Olaparib was dosed at 300 mg po bid until disease progression. A total of 12 out 19 pts (63%) the PFS ratio was ≥ 1.3, with a Wilson score 95% CI of (0.7, 3.). Nine out 12 pts (75%) with lBRCAm had increased PFS ratio. The 6-month PFS was 69.4% [95% CI: (40%, 86.4%)], and the 6-month OS was 88.8% [95% CI: (62.1%, 97.1%)] There was no Grade 3-4 toxicity. Conclusions: Olaparib monotherapy provided a statistically significant increment of PFS in almost 2/3 (63%) of heavily pretreated MBC pts harboring gBRCAm and lBRCAm. Interestingly, 75% of patients with lBRCAm resulted in improvement the PFS with minimal toxicity. Further research is necessary to extend the olaparib approval for lBRCAm in MBC pts.

20 May 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
GPGiuseppe Del Priore
Giuseppe Del Priore
SHSteve Hoffman
Steve Hoffman
Daniel NixonDaniel Nixon
Daniel Nixon
TPS2615 Background: Non-hormonal treatments for biochemically recurrent non-metastatic prostate cancer (nmPC) are limited. SM88 is a novel combination of proprietary tyrosine isomer (TI) and other repurposed agents (CYP3a4 inducer, mTOR inhibitor and catalyst) designed to selectively increase metabolic oxidative stress in cancer cells. Early data reported SM88 activity in solid tumors without significant toxicity (Hoffman et al J Clin Oncol 2013; e22095, Hoffman et al Ann Onc 2016: vi551). Methods: This is an open-label multi-center, dose escalating, dose expansion study in nmPC who have failed or refused androgen deprivation. The study includes a dose escalation phase Ib and dose expansion phase 2. The primary objectives are to determine the effect of SM88 on circulating tumor cells (CTC), and progression-free survival. Secondary objectives are: LDH, bone-specific alkaline phosphatase, urinary N-telopeptide, neutrophyll/llymphocyte ratio, cutaneous hyper-pigmentation correlation, PSA doubling times, safety, and patient reported outcomes. As of Jan ‘17, Phase 1b cohorts 1 and 2, with TI and component PK evaluations, have completed enrollment with adequate numbers to establish the Phase 2 dose without DLT. Phase 2 has begun, with 33 patients planned for at least 6 cycles (@28d) to reach the desired power. This would be followed by a pivotal Phase 3 study in the same group of patients. We propose to conduct a pivotal randomized phase 3 of SM88 in rising PSA, nmPC versus patient’s and clinician’s choice, limited to 2 options i.e. observation or ADT therapy. Inclusion would include doubling time < 9 months, elevated CTCs and recurrent disease after localized curative intent therapy (the same population as our completed Phase I and ongoing phase II). Outcomes will include delay of radiographic PFS, and delay of time to subsequent toxic therapy i.e. cytotoxic systemic chemo and/or radiation therapy. We proposed this pivotal trial will lead to a successful NDA for an indication in this population of patients. Rapid accrual is expected at several institutions because of the urgent need for less toxic alternatives to androgen deprivation therapy.

1 June 1994 in Cancer Prevention International
Verified
Journal Article
Closed access
Daniel NixonDaniel Nixon
Daniel Nixon